** Shares of drug developer Acadia Pharmaceuticals ACAD.O rise 34.2% to over 1-year high of $23.61
** U.S. District Court for the District of Delaware has ruled that India's Aurobindo Pharma infringes on two of Acadia Pharmaceuticals' patent claims
** The court has rejected Aurobindo's arguments that they are invalid
** The companies will meet to discuss next steps and submit a joint letter to the court within 21 days
** Acadia will provide an update on its revised stipulation regarding the patent claims within 7 days
** Companies must work together to redact sensitive information from the court's opinion and submit a proposed redacted version within 30 days
** Including session's move, stock up 28.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))